CenterWatch
  • Search Clinical Trials
  • Clinical Trial Listings
  • Volunteer
  • Learn About Clinical Trials

Baza, Spain

< 2 Miles
Filters

Type

Distance
Age
0
0
Gender
Trial Phase
Sponsor
  • OEA and LipiSperse Metabolic Study

    This study aims to compare the metabolic effects of two different doses of OEA with LipiSperse to a placebo in healthy participants over an 8-hour period. There are three trial arms in this study. Each participant will complete all 3 arms of the study, for a 3-way cross-over.

    Phase

    4

    Span

    52 weeks

    Sponsor

    RDC Clinical Pty Ltd

    Brisbane, Queensland

    Recruiting

    Healthy Volunteers

  • A Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BCX17725

    Parts 1 and 2 are randomized, placebo-controlled, single-ascending-dose (SAD) and multiple-ascending-dose (MAD) study parts, respectively, in healthy participants. Part 3 will evaluate multiple dose administrations in participants with Netherton syndrome in an open-label design.

    Phase

    1

    Span

    44 weeks

    Sponsor

    BioCryst Pharmaceuticals

    Brisbane, Queensland

    Recruiting

    Healthy Volunteers

  • A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis

    This study consists of 2 parts: Part A and Part B. Part A: Participants who did not participate in either parent study (TAK-279-3001 [NCT06088043] or TAK-279-3002 [NCT06108544]) may be enrolled and will be treated for up to 52 weeks. Participants who successfully complete Part A of the study are eligible to continue in Part B, but investigators must confirm their eligibility to continue in Part B. Part B: Participants who complete the treatment period of TAK-279-3001 (NCT06088043) or TAK-279-3002 (NCT06108544) parent studies or who complete Part A are eligible to enroll directly into open label extension treatment in Part B and will be treated for up to 156 weeks.

    Phase

    3

    Span

    88 weeks

    Sponsor

    Takeda

    Brisbane, Queensland

    Recruiting

  • A Study to Assess the Safety, Reactogenicity, and Immunogenicity of SK Japanese Encephalitis Messenger Ribonucleic Acid (mRNA) Vaccines (GBP560) in Healthy Adults

    The purpose of this study is to assess the safety, reactogenicity and immunogenicity of SK Japanese Encephalitis mRNA vaccines (GBP560) in healthy adults.

    Phase

    1/2

    Span

    160 weeks

    Sponsor

    SK Bioscience Co., Ltd.

    Brisbane

    Recruiting

    Healthy Volunteers

  • Long-Term PEA Safety Study

    This is an interventional, phase II, randomised, double-blind, placebo-controlled, parallel dose safety study in healthy adults to assess long term population exposure to Palmitoylethanolamide (Levagen™).

    Phase

    2

    Span

    106 weeks

    Sponsor

    RDC Clinical Pty Ltd

    Brisbane, Queensland

    Recruiting

    Healthy Volunteers

  • Nutrition in Paediatric Critical Care

    Phase

    N/A

    Span

    343 weeks

    Sponsor

    Australian and New Zealand Intensive Care Research Centre

    Brisbane

    Recruiting

  • Study of BM230 in Patients With Advanced Solid Tumors

    Phase

    1

    Span

    159 weeks

    Sponsor

    Suzhou Biomissile Pharmaceuticals Co., Ltd.

    Brisbane, Queensland

    Recruiting

  • A Study to Investigate the Feasibility and Respiratory Effects of Stimulating Two Functional Targets (neural And/or Muscular) for the Treatment of Obstructive Sleep Apnea

    Phase

    N/A

    Span

    57 weeks

    Sponsor

    Invicta Medical Inc.

    Brisbane, Queensland

    Recruiting

  • A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ≥18 Years of Age for the Prevention of Acute Gastroenteritis

    Phase

    3

    Span

    140 weeks

    Sponsor

    ModernaTX, Inc.

    Brisbane, Queensland

    Recruiting

    Healthy Volunteers

  • Study With [225Ac]Ac-FL-020 in mCRPC Participants

    The aim of this Phase 1, First-in-Human, Open-label Trial is to evaluate the safety, tolerability, pharmacokinetics, and efficacy of [225Ac]Ac-FL-020 as a single agent in participants with metastatic Castration-Resistant Prostate Cancer (mCRPC). [111In]In-FL-020 serves as a surrogate for 225Ac-FL-020 for dosimetry purposes. The trial is divided into two parts: dose escalation in Part 1 and cohort expansion in Part 2.

    Phase

    1

    Span

    122 weeks

    Sponsor

    Full-Life Technologies GmbH

    Brisbane

    Recruiting

1-10 of 211
CenterWatch

5000 Centregreen Way, Suite 200
Cary, NC, 27513, USA

Phone: 609.945.0101

  • Disclaimer
  • Privacy Policy
  • Term of Use
  • Do Not Sell My Personal Information